In a report released today, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Novavax (NVAX), with a price target of $20.00. The company’s shares closed last Monday at $12.74.
According to TipRanks.com, Mamtani has currently no stars on a ranking scale of 0-5 stars, with an average return of -7.8% and a 25.7% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.
Novavax has an analyst consensus of Strong Buy, with a price target consensus of $22.00, which is an 81.8% upside from current levels. In a report issued on March 12, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
Based on Novavax’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.82 million and GAAP net loss of $31.83 million. In comparison, last year the company earned revenue of $6.13 million and had a GAAP net loss of $49.33 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More on NVAX:
